Literature DB >> 26026056

Deficiency of CD40 Reveals an Important Role for LIGHT in Anti-Leishmania Immunity.

Ifeoma Okwor1, Guilian Xu2, Haidong Tang3, Yong Liang4, Yang-Xin Fu3, Jude E Uzonna5.   

Abstract

We previously showed that LIGHT and its receptor herpes virus entry mediator (HVEM) are important for development of optimal CD4(+) Th1 cell immunity and resistance to primary Leishmania major infection in mice. In this study, we further characterized the contributions of this molecule in dendritic cell (DC) maturation, initiation, and maintenance of primary immunity and secondary anti-Leishmania immunity. Flow-cytometric studies showed that CD8α(+) DC subset was mostly affected by HVEM-Ig and lymphotoxin β receptor-Ig treatment. LIGHT signaling is required at both the priming and the maintenance stages of primary anti-Leishmania immunity but is completely dispensable during secondary immunity in wild type mice. However, LIGHT blockade led to impaired IL-12 and IFN-γ responses and loss of resistance in healed CD40-deficient mice after L. major challenge. The protective effect of LIGHT was mediated primarily via its interaction with lymphotoxin β receptor on CD8α(+) DCs. Collectively, our results show that although LIGHT is critical for maintenance of primary Th1 response, it is dispensable during secondary anti-Leishmania immunity in the presence of functional CD40 signaling as seen in wild type mice.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26026056     DOI: 10.4049/jimmunol.1401892

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Leishmania major Infection-Induced VEGF-A/VEGFR-2 Signaling Promotes Lymphangiogenesis That Controls Disease.

Authors:  Tiffany Weinkopff; Christoph Konradt; David A Christian; Dennis E Discher; Christopher A Hunter; Phillip Scott
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

Review 2.  Unraveling the Role of Immune Checkpoints in Leishmaniasis.

Authors:  Rafael de Freitas E Silva; Esther von Stebut
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

3.  HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.

Authors:  Weifeng Liu; Ting-Fang Chou; Sarah C Garrett-Thomson; Goo-Young Seo; Elena Fedorov; Udupi A Ramagopal; Jeffrey B Bonanno; Qingyang Wang; Kenneth Kim; Scott J Garforth; Kiyokazu Kakugawa; Hilde Cheroutre; Mitchell Kronenberg; Steven C Almo
Journal:  J Exp Med       Date:  2021-10-28       Impact factor: 14.307

4.  Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis.

Authors:  Nidhi S Dey; Sujai Senaratne; Vijani Somaratne; Nayani P Madarasinghe; Bimalka Seneviratne; Sarah Forrester; Marcela Montes de Oca; Luiza Campos Reis; Srija Moulik; Pegine B Walrad; Mitali Chatterjee; Hiro Goto; Renu Wickremasinghe; Dimitris Lagos; Paul M Kaye; Shalindra Ranasinghe
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.